Absence of Common Somatic Alterations in Genes on 1p and 19q in Oligodendrogliomas

A common and histologically well defined subtype of glioma are the oligodendroglial brain tumors. Approximately 70% of all oligodendrogliomas have a combined loss of the entire 1p and 19q chromosomal arms. This remarkably high frequency suggests that the remaining arms harbor yet to be identified tumor suppressor genes. Identification of these causal genetic changes in oligodendrogliomas is important because they form direct targets for treatment. In this study we therefore performed targeted resequencing of all exons, microRNAs, splice sites and promoter regions residing on 1p and 19q on 7 oligodendrogliomas and 4 matched controls. Only one missense mutation was identified in a single sample in the ARHGEF16 gene. This mutation lies within- and disrupts the conserved PDZ binding domain. No similar ARHGEF16 mutations or deletions were found in a larger set of oligodendrogliomas. The absence of common somatic changes within genes located on 1p and 19q in three out of four samples indicates that no additional “second hit” is required to drive oncogenic transformation on either chromosomal arm.

[1]  C. Hoogenraad,et al.  IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo , 2011, Annals of neurology.

[2]  S. Mane,et al.  K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension , 2011, Science.

[3]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[4]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[5]  M. J. van den Bent,et al.  Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? , 2011, The Lancet. Oncology.

[6]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[7]  C. Hoogenraad,et al.  Integrated genomic profiling identifies candidate genes implicated in glioma‐genesis and a novel LEO1‐SLC12A1 fusion gene , 2010, Genes, chromosomes & cancer.

[8]  C. Hoogenraad,et al.  Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma , 2010, Human mutation.

[9]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[10]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[11]  H. Kitchener,et al.  Analogues of Y27632 increase gap junction communication and suppress the formation of transformed NIH3T3 colonies , 2009, British Journal of Cancer.

[12]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[13]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[14]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[15]  G. Reifenberger,et al.  Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss , 2008, International journal of cancer.

[16]  A. Mills,et al.  The quest for the 1p36 tumor suppressor. , 2008, Cancer research.

[17]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[18]  M. J. van den Bent,et al.  Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. , 2007, Cancer research.

[19]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[20]  H. Vogel,et al.  CHD5 Is a Tumor Suppressor at Human 1p36 , 2007, Cell.

[21]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[22]  G. Reifenberger,et al.  Identification of novel oligodendroglioma‐associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray‐based expression profiling , 2006, International journal of cancer.

[23]  司履生 Cancer epigenetics , 2006 .

[24]  Jord H A Nagel,et al.  Gene expression profiles associated with treatment response in oligodendrogliomas. , 2005, Cancer research.

[25]  S. Batzoglou,et al.  Distribution and intensity of constraint in mammalian genomic sequence. , 2005, Genome research.

[26]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.

[27]  Miguel Alaminos,et al.  EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. , 2005, Cancer research.

[28]  Marc Ladanyi,et al.  Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  P. Laird Cancer epigenetics. , 2005, Human molecular genetics.

[30]  R. McLendon,et al.  Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.

[31]  D. Horsman,et al.  Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity , 2003, Journal of Neuro-Oncology.

[32]  J. Menten,et al.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. J. van den Bent,et al.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.

[34]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[35]  Takaaki Kirino,et al.  Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[37]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.